Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Horm Res
What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy
Given BPC-157's angiogenic properties (VEGF upregulation), theoretical concern exists about promoting vascular growth in hepatocellular carcinoma, though no case reports have documented this outcome [1]
Key Takeaways ARA-290 (cibinetide) is derived from erythropoietin without erythropoietic effects It activates the innate repair receptor It reduces inflammation while preserving immune function It supports nerve repair and tissue protection It has been studied extensively in neuropathic and inflammatory conditions It fits naturally into an integrative medicine framework The Bigger Picture ARA-290 represents a shift away from symptom-focused medicine toward cellular repair biology
